Q-Linea Q2 FY26 operating loss narrows to SEK 31.3 million; net sales rise to SEK 1.5 million

  • Q-Linea posted Q2 EBIT of SEK -31.3 million, narrowing from SEK -47.3 million a year earlier.
  • Net sales rose 36.36% to SEK 1.5 million; contracted ASTar instruments climbed to 24 from 12 at quarter-end.
  • H1 net sales fell 27.08% to SEK 3.5 million; EBIT improved to SEK -66.3 million from SEK -91.9 million.
  • Net cash position totaled SEK 186.8 million at June 30, up from SEK 82.7 million a year earlier.
  • Q2 included FDA clearance for an expanded U.S. ASTar blood-testing menu; management reiterated a cost outlook below SEK 11 million per month.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q-Linea AB published the original content used to generate this news brief on July 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.